Newsletters

Dear All (and with thanks to Lucy Naga for being the lead author on this economic-focused newsletter), Antimicrobials are the ...

Dear All, You may recall that in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A ...

Dear All, No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is ...

Dear All, A very senior and globally significant leadership opportunity has appeared: CARB-X is seeking to recruit a new Chief of Research ...

Dear All (and with thanks to Robert Skov for co-authoring this newsletter AND with a wonkish alert for this complicated ...

Dear All, In a thoughtful companion to WHO’s preclinical and clinical pipeline reviews, we now have an instructive analysis of ...

Dear All, I just today learned that FDA has posted two antimicrobial resistance-related (AMR-related) FY 2026 funding opportunities. The titles ...

Dear All, Happy New Year! As a great start for January, Team CARB-X have announced (i) that they will have two ...

Dear All, In a paper that is clearly a labor of love (1,032 references!), Mark Butler and Robert Capon have ...

Note: As always, please use the copy of the newsletter posted at https://amr.solutions/ if you have trouble with links in this ...

Dear All, The 8 Dec 2025 newsletter entitled “Phage therapy: Regulatory perspectives from TATFAR” generated a fair bit of commentary! ...

Dear All, Integrating perspectives from EC HERA, EMA, Health Canada, Norway, UK MHRA, US FDA, and US NIH, the Transatlantic ...

Dear All, On 26 Nov 2026, the Antimicrobial Resistance Surveillance & Research Initiative (AMRSRN) of the Indian Council on Medical Research ...

Dear All, Recently posted, six concepts were approved for FY 2027 funding at the September 2025 meeting of NIAID’s Division of Microbiology and ...